Biogen Inc and Japanese partner Eisai Co said on Thursday the U.S. Food and Drug Administration (FDA) had granted 'fast track' designation to their experimental therapy, lecanemab, for the treatment of early Alzheimer's disease.
said on Thursday the U.S. Food and Drug Administration had granted "fast track" designation to their experimental therapy, lecanemab, for the treatment of early Alzheimer's disease.
FDA had granted "breakthrough" therapy designation to the drug earlier this year despite an outside advisory panel saying its clinical benefit was unproven. The drug works in a similar manner to Biogen's Aduhelm and gets rid of sticky deposits of a protein called amyloid beta from brains of patients in the initial stages of the disease to mitigate its impact.The fast track status is designed to expedite the review of treatments and vaccines meant for serious conditions. A vaccine or treatment that gets the status is eligible for more frequent meetings with the FDA.
The companies have jointly developed three experimental drugs for the disease, which affects millions around the world and has not seen a new treatment in decades. The drug's development was nearly abandoned after disappointing trial results in 2019, but Biogen revived it after reviewing data that showed higher doses of the drug could slow disease progression.Reporting by Vishal Vivek in Bengaluru; Editing by Vinay DwivediSubscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
What’s Behind Biogen’s Move To Cut Prices On Its Controversial Alzheimer’s Drug Aduhelm?This week, drugmaker Biogen made a stunning announcement: It is going to cut in half the price of its controversial Alzheimer’s drug Aduhelm.
Weiterlesen »
FDA clears second at-home Covid treatment, from MerckThe FDA's authorization of Merck's oral antiviral drug molnupiravir comes despite the agency's advisory committee expressing concerns about the safety and efficacy of the drug.
Weiterlesen »
FDA authorizes Merck's COVID pill for some high-risk adultsThe Food and Drug Administration on Thursday authorized an antiviral pill developed by Merck and Ridgeback Biotherapeutics to treat some adults at high risk of becoming severely ill from COVID-19, despite concerns over its effectiveness and safety. Why it matters: Effective at-home antiviral drugs designed to prevent or treat COVID-19 could be key pandemic-fighting tools, especially as new variants emerge. Stay on top of the latest market trends and economic insights with Axios Markets. Subscrib
Weiterlesen »
FDA OKs Emergency Use of Merck Pill for COVID-19The FDA has granted emergency use authorization to Merck’s antiviral drug to treat adults with mild to moderate COVID-19 who are at risk for severe disease.
Weiterlesen »